Procept Biorobotics stock hits 52-week low at 26.65 USD By Investing.com
Procept BioRobotics (PRCT) stock has fallen to a new 52-week low of $26.65, representing a significant decline of over 59% in the past year. Despite this, InvestingPro data suggests the company is undervalued, boasts strong revenue growth of 50.07%, and holds more cash than debt. Analysts have offered mixed evaluations, with UBS initiating a 'Buy' rating and BofA Securities downgrading to 'Neutral' due to decelerating utilization growth of their aquablation technology.
Wall Street Has a Positive Opinion on PROCEPT BioRobotics (PRCT), Here's Why
Wall Street analysts are optimistic about PROCEPT BioRobotics (PRCT) ahead of its Q4 2025 earnings report, with expectations for strong revenue and GAAP EPS. Despite one analyst maintaining a Hold rating, the majority hold Buy ratings, and the average price target suggests significant upside. The company specializes in surgical robotics for urology with its AquaBeam Robotic System.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Recommendation of "Moderate Buy" by Brokerages
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year target price of $53.40 despite several recent price target reductions. The company, which specializes in robotic systems for benign prostatic hyperplasia (BPH) treatment, showed a 42.6% year-over-year revenue growth and beat earnings per share estimates, though it remains unprofitable. Institutional ownership is high at almost 90%, and the stock recently opened at $28.74.
C WorldWide Group Holding A S Invests $5.35 Million in PROCEPT BioRobotics Corporation $PRCT
C WorldWide Group Holding A S has invested $5.35 million in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by acquiring a new 150,000-share stake. This investment represents 0.27% of the company, which recently reported better-than-expected Q3 EPS and revenue growth of 42.6% year-over-year, despite remaining unprofitable with negative margins. Analysts currently rate PROCEPT BioRobotics as a "Moderate Buy" with a consensus price target of $53.40.
Procept Biorobotics stock hits 52-week low at 27.79 USD
Procept Biorobotics Corp's stock has dropped to a 52-week low of $27.79, reflecting a 60.6% decline over the past year. This comes despite a reported 3% revenue beat in Q3, with analysts offering mixed outlooks, including price target reductions by TD Cowen and Leerink Partners, a downgrade by BofA Securities, and an optimistic "Buy" rating from UBS. The varied analyst opinions highlight uncertainty surrounding future growth and market perception of the company.
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management will present at two upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference. During these events, the company will discuss its surgical robotics solutions for urology, specifically focusing on its AQUABEAM® and HYDROS® Robotic Systems for BPH treatment. Webcasts of the fireside chats will be available on the company's investor relations website.
(PRCT) Risk Channels and Responsive Allocation
This article analyzes Procept Biorobotics Corporation (NASDAQ: PRCT), indicating weak sentiment across all horizons and supporting a short bias. It highlights an exceptional 82.0:1 risk-reward setup targeting a 23.9% gain versus 0.3% risk, driven by a mid-channel oscillation pattern. Three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined, each tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management will present at two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference. The company specializes in surgical robotics, particularly the AQUABEAM® and HYDROS® Robotic Systems, which utilize Aquablation therapy for treating BPH. Webcasts of the presentations will be available on the company's investor relations website.
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
PROCEPT BioRobotics (Nasdaq: PRCT) announced that its management will present at two upcoming investor conferences in March: the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference. Live webcasts and archived recordings of these events will be available on the company's investor relations website. PROCEPT BioRobotics is a surgical robotics company focused on urology, manufacturing the AQUABEAM® and HYDROS® Robotic Systems for BPH treatment.
Surgery robot firm PROCEPT plans Feb. 25 investor day at Nasdaq HQ
PROCEPT BioRobotics (Nasdaq: PRCT) announced it will report its fourth-quarter 2025 financial results on Tuesday, February 24, 2026, after market close, followed by a conference call. The company will also host an in-person Investor Day at NASDAQ Headquarters in New York City on Wednesday, February 25, 2026, starting at 8:00 a.m. ET. Both events will be webcast live and archived on the company's investors' website.
PROCEPT BioRobotics to Report Q4 2025 Financial Results and Host Investor Day Event in February 2026
PROCEPT BioRobotics Corporation announced it will release its fourth-quarter 2025 financial results on February 24, 2026, followed by a conference call. The company will also host an in-person investor day at NASDAQ Headquarters on February 25, 2026. Both events will be live-streamed and archived, highlighting the company's focus on advancing urological care with its AI-powered AQUABEAM® and HYDROS® Robotic Systems for treating benign prostatic hyperplasia (BPH).
Did AquaBeam Milestones and Options Activity Just Shift PROCEPT BioRobotics' (PRCT) Investment Narrative?
PROCEPT BioRobotics is gaining investor attention due to its AquaBeam Robotic System for benign prostatic hyperplasia, with trading activity influenced by upcoming regulatory and clinical milestones. The company's investment narrative centers on the AquaBeam system's adoption and reimbursement, despite current unprofitability and high sales multiples. While analysts have diverse fair value estimates, the article suggests investors build their own narrative based on the company's financial health and market catalysts.
A Look At PROCEPT BioRobotics (PRCT) Valuation As Regulatory And Clinical Catalysts Draw Investor Focus
PROCEPT BioRobotics (PRCT) is back in focus due to upcoming regulatory decisions and clinical trial readouts for its AquaBeam Robotic System, despite a 55.87% decline in shareholder return over the past year. Analysts estimate a fair value of $50.73 per share, significantly above its current trading price of $30.73, suggesting it is undervalued, yet its Price to Sales ratio is higher than industry averages, indicating potential valuation risk if growth expectations are not met. The company's valuation hinges on sustained growth, improved margins, and increasing procedure volumes.
First Week of March 20th Options Trading For PROCEPT BioRobotics (PRCT)
New options contracts for PROCEPT BioRobotics (PRCT) with a March 20th expiration date have become available. BNK Invest's YieldBoost analysis identified a put contract at a $25.00 strike price and a call contract at a $32.50 strike price as being particularly interesting for investors. The article details potential returns and risks for selling these options, based on PRCT's current trading price of $30.29/share.
FMR LLC Reduces Stake in PROCEPT BioRobotics Corp by 42.10%
FMR LLC (Fidelity) has significantly reduced its stake in PROCEPT BioRobotics Corp (PRCT) by 42.10%, selling 3,382,944 shares. This strategic move highlights Fidelity's adjustment in its growth-oriented portfolio, despite PROCEPT BioRobotics being considered significantly undervalued with strong growth potential in the surgical robotics sector. The transaction had a minimal impact on FMR LLC's overall portfolio, but indicates a re-evaluation of risk or optimization of returns for the investment firm.
Liquidity Mapping Around (PRCT) Price Events
This article from Stock Traders Daily discusses Procept Biorobotics Corporation (NASDAQ: PRCT) and its price events. It highlights near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. The analysis provides specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging trading strategies based on AI models.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Recommendation of "Moderate Buy" by Analysts
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received an average "Moderate Buy" rating from thirteen analysts, with an average 12-month price target of $53.40. Institutions and hedge funds own a significant 89.46% of the stock, with several firms increasing their stakes. Despite being unprofitable, the company reported a 42.6% YoY revenue increase and beat EPS estimates last quarter, while analysts project an EPS of -1.75 for the current year.
Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views
PROCEPT BioRobotics (PRCT) is under scrutiny following an analyst downgrade from Bank of America, despite continued long-term growth optimism. Currently trading at a significant discount to the average analyst target of US$50.73, the company's valuation prompts questions about whether it's an undervalued growth story or if its high P/S ratio (6.1x sales) already reflects growth expectations. The positive long-term narrative hinges on Aquablation technology's continued success, clinical trial progress, and market expansion.
Peregrine Capital Management LLC Purchases Shares of 188,219 PROCEPT BioRobotics Corporation $PRCT
Peregrine Capital Management LLC has acquired a new stake of 188,219 shares, valued at approximately $6.72 million, in PROCEPT BioRobotics Corporation (NASDAQ:PRCT). This purchase represents about 0.34% of the company. Despite reporting Q3 revenue of $83.33 million (up 42.6% year-over-year) and beating EPS estimates, PROCEPT BioRobotics remains unprofitable with a negative net margin and return on equity, though analysts maintain a "Moderate Buy" rating with a $53.40 average price target.
Is Wall Street’s Split View On PROCEPT BioRobotics (PRCT) Revealing Aquablation’s True Strategic Position?
Recent analyst updates on PROCEPT BioRobotics (PRCT) show a split view regarding its Aquablation technology for benign prostatic hyperplasia. While some analysts, like UBS, are optimistic about utilization growth, Bank of America downgraded the stock due to concerns over slowing adoption. This divergence highlights that investor expectations are highly sensitive to the procedural volumes and continued market penetration of Aquablation, which is critical for PROCEPT to overcome ongoing losses and high R&D spending.
Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation
Truist has reiterated its Buy rating on Procept BioRobotics (PRCT) but lowered its price target to $47, citing a positive long-term view of the MedTech sector despite potential short-term capitalization challenges. This positive outlook is supported by a recent Buy initiation from UBS, which highlighted the company's potential for utilization growth and new system placements. However, Bank of America downgraded PRCT to Neutral, expressing concerns over slowing utilization growth for its aquablation technology.
Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation
Truist has maintained its Buy rating on Procept BioRobotics (PRCT), despite lowering its price target to $47 from $50, as part of a 2026 MedTech sector preview, seeing attractive valuations but cautioning on capital flow. UBS also initiated coverage with a Buy rating and a $62 price target, confident in utilization growth. Conversely, Bank of America downgraded PRCT to Neutral with a $38 price target due to concerns about slowing utilization growth and short-term operational friction.
Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation
Truist maintained its Buy rating on Procept BioRobotics (PRCT) but lowered its price target to $47 from $50, anticipating a MedTech sector rotation in 2026. The firm prefers companies with catalysts for long-term growth, and UBS also initiated coverage with a Buy rating and $62 target due to overlooked core strengths. However, Bank of America downgraded PRCT to Neutral with a $38 target, citing concerns over slowing utilization growth despite the potential of its aquablation technology.
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: A 53% Potential Upside in the Surgical Robotics Arena
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is gaining investor interest with its surgical robotics technology for benign prostatic hyperplasia (BPH) treatment. Analysts project a 53.16% upside for the stock, with a consensus of mostly "buy" ratings. While the company is not yet profitable, it demonstrates strong revenue growth, positioning it for potential long-term gains in the evolving healthcare sector.
PROCEPT BioRobotics Corporation $PRCT Shares Purchased by Chicago Capital LLC
Chicago Capital LLC significantly increased its stake in PROCEPT BioRobotics (PRCT) by 175.7% in Q3, now owning 1,568,845 shares valued at approximately $56.0 million. This makes PRCT the 27th largest holding for Chicago Capital LLC, representing 2.82% ownership. Analysts rate the stock a "Moderate Buy" with a consensus target price of $53.40, following strong Q3 revenue and EPS beats.
Why (PRCT) Price Action Is Critical for Tactical Trading
This article examines the price action of Procept Biorobotics Corporation (NASDAQ: PRCT), highlighting weak sentiment across all time horizons and suggesting a short bias. It outlines detailed institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The article emphasizes AI-generated signals and risk-reward setups for tactical trading.
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook
UBS analyst Danielle Antalffy initiated coverage of PROCEPT BioRobotics (PRCT) with a bullish view, emphasizing potential profitability by 2027 driven by expanding revenue, improving gross margins, and cost efficiencies. This adds to existing optimistic sentiment surrounding the company's Aquablation-based procedures, despite current operating losses and a high valuation. Investors should still consider the risk of continued losses overshadowing the target profitability.
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook
UBS has initiated coverage on PROCEPT BioRobotics (PRCT) with a bullish outlook, projecting profitability by 2027 driven by expanding revenue, improved gross margins, and cost efficiencies. This positive sentiment reinforces existing analyst optimism regarding the company's Aquablation-based surgical robotics platform. Despite current losses and a high valuation, PROCEPT's reaffirmed 2025 and new 2026 revenue guidance support the bullish stance, though investors should acknowledge the risks associated with ongoing operating losses and high R&D spending.
15 Most Promising Mid-Cap Healthcare Stocks Under $50
This article, part of a larger list, highlights Procept BioRobotics Corp. (NASDAQ: PRCT) as a promising mid-cap healthcare stock under $50. Analysts are bullish on PRCT, with a high percentage of Buy ratings and a significant potential upside, driven by the company's growth prospects in surgical robotics for male urological health.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Moderate Buy" by Brokerages
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $53.40. Key financial results show revenue of $83.33M (up 42.6%) and an EPS loss of ($0.38) that beat estimates, though the company remains unprofitable. Institutional investors hold approximately 89.46% of the stock.
Transcript : PROCEPT BioRobotics Corporation Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 08
PROCEPT BioRobotics Corporation presented at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation featured Matt O'Brien, one of Piper's med tech analysts, introducing PROCEPT BioRobotics. Full details of the transcript are reserved for subscribers.
Squarepoint Ops LLC Decreases Stake in PROCEPT BioRobotics Corporation $PRCT
Squarepoint Ops LLC significantly reduced its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 27.9% in Q2, while institutional investors collectively own about 89.46% of the company. Despite the selling, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $53.70. PROCEPT BioRobotics exceeded Q3 earnings and revenue estimates but remains unprofitable with negative margins.
PROCEPT BioRobotics Corporation $PRCT Shares Bought by Eventide Asset Management LLC
Eventide Asset Management LLC significantly increased its stake in PROCEPT BioRobotics Corporation ($PRCT) by 33.1% in Q2, boosting its ownership to 468,476 shares valued at $27.0 million. This move contributes to the company's high institutional ownership of 89.46%, despite the company remaining unprofitable with negative net margins. Wall Street analysts maintain a "Moderate Buy" consensus rating for PROCEPT BioRobotics, with an average target price of $53.70, even after some target price adjustments.
UBS Initiates Coverage of PROCEPT BioRobotics (PRCT) with Buy Recommendation
UBS has initiated coverage on PROCEPT BioRobotics (PRCT) with a Buy recommendation and a one-year average price target of $54.80, suggesting a 52.27% upside from its last closing price. The company projects annual revenue of $311MM and a non-GAAP EPS of -1.51. Institutional ownership remains strong with several funds holding significant positions, and the put/call ratio indicates a bullish outlook for PRCT.
UBS initiates Procept BioRobotics stock with Buy rating on utilization growth
UBS has initiated coverage on Procept BioRobotics Corp (NASDAQ:PRCT) with a Buy rating and a $62.00 price target, citing expected utilization growth in 2026 and 2027. The investment bank's analysis places its sales estimates ahead of consensus and underscores Procept's strong financial foundation and potential for margin expansion. Despite not yet being profitable, the company demonstrated impressive revenue growth and has upcoming catalysts that could re-rate the stock to valuations more in line with high-growth medical technology peers.
UBS initiates Procept BioRobotics stock with Buy rating on utilization growth
UBS has initiated coverage on Procept BioRobotics Corp (NASDAQ:PRCT) with a Buy rating and a $62.00 price target, anticipating significant utilization growth in 2026 and 2027. The firm believes the market undervalues Procept's focus on driving utilization of its existing installed base, the large total addressable market, and potential margin expansion. Despite not yet being profitable, the company demonstrates strong financial foundations and impressive revenue growth.
Precision Trading with Procept Biorobotics Corporation (PRCT) Risk Zones
This article provides a detailed analysis of Procept Biorobotics Corporation (PRCT) with AI-generated trading strategies and risk zones. It outlines near-term and mid-term sentiment, long-term outlook, and specific entry, target, and stop-loss points for long, breakout, and short positions. The analysis emphasizes risk management and various time horizon signals for traders.
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by Thematics Asset Management
Thematics Asset Management significantly increased its stake in PROCEPT BioRobotics by 74.5%, now holding 394,709 shares, representing about 0.71% of the company. Other institutional investors also raised their positions, bringing total institutional ownership to approximately 89.46%. Despite reporting strong quarterly revenue growth of 42.6% year-over-year that beat estimates, PROCEPT BioRobotics remains unprofitable, with a negative net margin and return on equity, and analysts have a "Moderate Buy" consensus rating with an average price target of $57.89.
UBS initiates Procept BioRobotics stock with Buy rating on utilization growth
UBS has initiated coverage on Procept BioRobotics Corp (NASDAQ:PRCT) with a Buy rating and a $62.00 price target, citing expected utilization growth in 2026 and 2027. The investment bank's analysis suggests significant growth potential, with estimates for U.S. utilization growth surpassing consensus and the market underappreciating Procept's strategy for driving utilization. Despite recent mixed analyst outlooks, Procept's strong financial foundation and impressive revenue growth support a positive long-term view.
Axa S.A. Purchases 63,519 Shares of PROCEPT BioRobotics Corporation $PRCT
Axa S.A. has increased its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 8.1% in Q2, acquiring 63,519 shares to hold a total of 850,490 shares valued at approximately $48.99 million. Other major institutions like AllianceBernstein and State Street have also increased their positions, contributing to institutional ownership of 89.46% of the float. Analysts maintain a "Moderate Buy" rating with a consensus price target of $52.78, following the company's strong revenue growth and an EPS beat in its latest quarterly report.
PROCEPT BioRobotics Faces Slower Growth As BofA Lowers Rating
PROCEPT BioRobotics' shares dipped after BofA Securities downgraded the company due to slower-than-expected adoption of its aquablation therapy for BPH, leading to a reduced price target of $38 from $55. Despite potential for solid growth (20% annual revenue growth to reach operating profitability by 2029), market hurdles like prostate size limits, cost, and competition are slowing its market penetration. This highlights the challenges even advanced medical therapies face in real-world adoption.
PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says
BofA Securities noted that PROCEPT BioRobotics (PRCT) possesses a large market opportunity, but its utilization growth has recently slowed. Despite this, the company, known for its AQUABEAM Robotic System for benign prostatic hyperplasia (BPH) treatment, maintains strong analyst support with a "Buy" consensus from 12 analysts and an average target price significantly above its last close.
Procept BioRobotics stock downgraded by BofA on slowing growth
BofA Securities downgraded Procept BioRobotics (NASDAQ:PRCT) from Buy to Neutral and lowered its price target due to slowing utilization growth of its aquablation technology. This slowdown and increased scrutiny on hospital capital spending have led to a multiple contraction in its valuation. Despite the downgrade, Procept BioRobotics holds more cash than debt and has a strong current ratio, indicating financial flexibility.
Mackenzie Financial Corp Buys New Stake in PROCEPT BioRobotics Corporation $PRCT
Mackenzie Financial Corp acquired a new stake of 708,656 shares in PROCEPT BioRobotics Corporation ($PRCT), valued at approximately $40.82 million, representing 1.27% ownership. Despite beating estimates on EPS and revenue last quarter, PROCEPT remains unprofitable. Analysts currently have a "Moderate Buy" rating with a consensus target price of $59.78, while the stock trades near $31.68.
Champlain Investment Partners LLC Buys 394,450 Shares of PROCEPT BioRobotics Corporation $PRCT
Champlain Investment Partners LLC significantly increased its stake in PROCEPT BioRobotics Corporation, purchasing an additional 394,450 shares in Q2, bringing its total to over 1 million shares valued at $61.67 million. Despite being unprofitable, PROCEPT BioRobotics exceeded revenue and EPS estimates in its latest quarter, prompting a "Moderate Buy" consensus rating from analysts with an average price target of $59.78. Institutional investors collectively own a substantial 89.46% of the company's stock.
PROCEPT BioRobotics To Spotlight Aquablation Growth At Piper Sandler Event Next Month
PROCEPT BioRobotics Corp. (PRCT) will showcase its Aquablation therapy and HYDROS Robotic System at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. The company recently reported strong Q3 2025 financial results, with revenue up 43% year-over-year to $83.3 million and an updated full-year revenue guidance of $325.5 million for fiscal year 2025. This presentation underscores the company's focus on expanding awareness and long-term growth for its urology solutions.
PROCEPT BioRobotics® to Present at Upcoming 37th Annual
PROCEPT BioRobotics (Nasdaq: PRCT) announced that members of its management team will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on the "Investors" section of the company’s website. The company focuses on developing robotic solutions for BPH treatment and manufactures the AQUABEAM® and HYDROS® Robotic Systems.
PROCEPT BioRobotics (NASDAQ: PRCT) to present at 37th Annual Piper Sandler Conference
PROCEPT BioRobotics (NASDAQ: PRCT) announced that management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, December 2, 2025, at 8:30 a.m. ET. A live webcast and archived recording will be available on the company’s Investors section. The news of the presentation on December 2, 2025, led to a slight decline of 0.14% in PRCT stock, indicating a mild negative market reaction, despite a peak movement of +4.3% during the session.
Piper Sandler Reiterates a Buy on PROCEPT BioRobotics Corporation (PRCT)
Piper Sandler reiterated a Buy rating on PROCEPT BioRobotics Corporation (PRCT) with a $50 price target, despite an earlier reduction from $55. The company exceeded Q3 2025 revenue and EPS estimates due to strong demand for its HYDROS Robotic System and Aquablation therapy. Analyst Matthew O'Brien acknowledges potential concerns about soft utilization performance but believes these issues are temporary and expects positive future results.
Piper Sandler Reiterates a Buy on PROCEPT BioRobotics Corporation (PRCT)
Piper Sandler analyst Matthew O’Brien reiterated a Buy rating and a $50 price target on PROCEPT BioRobotics Corporation (PRCT) despite a previous price target reduction. The company exceeded expectations in Q3 2025 with strong revenue growth attributed to demand for its HYDROS Robotic System and Aquablation therapy. The analyst views temporary issues like soft utilization and investor destocking as short-lived and anticipates positive outcomes from internal company changes.
